Project Details
Description
A Phase IIIb, multi-center, double-blind, placebo-controlled, randomized trial to examine the corticosteroid-sparing effect of certolizumab pegol(COSPAR 1)
| Status | Finished |
|---|---|
| Effective start/end date | 8/10/06 → 12/31/08 |
Funding
- Pharmaceutical Product Development, Inc.
- UCB PHARMA S.A.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.